Estudo experimental da inibição do VEGF na regeneração hepática

Detalhes bibliográficos
Autor(a) principal: Sousa, Eros Luiz de
Data de Publicação: 2019
Tipo de documento: Tese
Idioma: por
Título da fonte: Biblioteca Digital de Teses e Dissertações do Mackenzie
Texto Completo: https://dspace.mackenzie.br/handle/10899/28448
Resumo: Background: extensive liver resections and transplants of liver parts are possible thanks to its regenerative capacity which is dependent on vascular endothelial growth factor (VEGF) activation which also regulates the angiogenesis. Bevacizumab (BV), a monoclonal antibody VEGF inhibitor, is a neoadjuvant treatment of cancers widely used, restricting microvascular density and may cause undesirable effects on postoperative healing and liver regeneration (LR). Objective: to determine the effect of a single dose (5mg/kg) of BV in LR. Methods: 32 rats submitted to partial hepatectomy (PH) were separated into two groups according to saline solution (C) or BV (BV) treatment. According to the observation time (48h and 15 days) they were subdivided in C48 and BV48 and C15 and BV15 sub-groups. In LR, the BV effects were evaluated by weight variation and liver function (albumin, transaminase, bilirubin and APRI ratio) and in remaining liver were evaluated, mitotic activity, microvascular density (angiogenesis), nuclear proliferation, histopathology for fibrosis, edema and congestion. For statistical analysis, the ANOVA and T-Student test was used (of statistical significance when p≤0.05). Results: on the fifteenth day after PH and BV treatment, there were no differences in weight evaluations (p=0.0691), liver function and mitotic indexes (p=0.1576). However, there was a decrease in cell viability (p=0.0000), microvascular density (p = 0.0162) and worsening in the occurrence of histopathological changes such as liver fibrosis, edema and congestion. Conclusion: a single BV dose, on the fifteenth day of evolution has no significant effect in weight evolution, serum biochemical evaluations (albumin, bilirubin and transaminases) and mitotic index. However, it induced microvascular density decreased, cell viability and liver histopathological changes such as fibrosis, edema and congestion.
id UPM_53192a66f80d676c81fa3a7dde02038d
oai_identifier_str oai:dspace.mackenzie.br:10899/28448
network_acronym_str UPM
network_name_str Biblioteca Digital de Teses e Dissertações do Mackenzie
repository_id_str 10277
spelling http://lattes.cnpq.br/0300957415364593Sousa, Eros Luiz deMalafaia, Osvaldohttp://lattes.cnpq.br/75642003460452042021-12-15T19:34:01Z2021-12-15T19:34:01Z2019-01-09Background: extensive liver resections and transplants of liver parts are possible thanks to its regenerative capacity which is dependent on vascular endothelial growth factor (VEGF) activation which also regulates the angiogenesis. Bevacizumab (BV), a monoclonal antibody VEGF inhibitor, is a neoadjuvant treatment of cancers widely used, restricting microvascular density and may cause undesirable effects on postoperative healing and liver regeneration (LR). Objective: to determine the effect of a single dose (5mg/kg) of BV in LR. Methods: 32 rats submitted to partial hepatectomy (PH) were separated into two groups according to saline solution (C) or BV (BV) treatment. According to the observation time (48h and 15 days) they were subdivided in C48 and BV48 and C15 and BV15 sub-groups. In LR, the BV effects were evaluated by weight variation and liver function (albumin, transaminase, bilirubin and APRI ratio) and in remaining liver were evaluated, mitotic activity, microvascular density (angiogenesis), nuclear proliferation, histopathology for fibrosis, edema and congestion. For statistical analysis, the ANOVA and T-Student test was used (of statistical significance when p≤0.05). Results: on the fifteenth day after PH and BV treatment, there were no differences in weight evaluations (p=0.0691), liver function and mitotic indexes (p=0.1576). However, there was a decrease in cell viability (p=0.0000), microvascular density (p = 0.0162) and worsening in the occurrence of histopathological changes such as liver fibrosis, edema and congestion. Conclusion: a single BV dose, on the fifteenth day of evolution has no significant effect in weight evolution, serum biochemical evaluations (albumin, bilirubin and transaminases) and mitotic index. However, it induced microvascular density decreased, cell viability and liver histopathological changes such as fibrosis, edema and congestion.Introdução: extensas ressecções e transplantes de partes do fígado são possíveis, graças à sua capacidade regenerativa que é dependente da ativação do fator de crescimento vascular endotelial (VEGF) o qual também regula angiogênese. O bevacizumabe (BV), anticorpo monoclonal inibidor do VEGF é um neoadjuvante amplamente utilizado no tratamento de cânceres restringindo a densidade microvascular, podendo causar efeitos indesejáveis na cicatrização pós-operatória e na regeneração hepática. Objetivo: avaliar a regeneração hepática (RH), pós hepatectomia a 70%, sob ação de uma dose (5mg/kg) de BV num modelo experimental murino, durante 15 dias. Métodos: utilizaram-se 32 ratos Wistar submetidos à hepatectomia parcial (HP), separados em dois grupos conforme o tratamento controle (C) tratados com solução fisiológica e BV tratados com BV, subdivididos conforme o tempo de observação (48 horas e 15 dias) em C48, BV48 e C15, BV15. Os efeitos do BV na RH foram avaliados nas avaliações ponderais, função hepática (albumina, transaminases, bilirrubinas e relação APRI). No fígado remanescente avaliaram-se atividade mitótica, densidade microvascular (angiogênese), proliferação nuclear, histopatologia para investigar fibrose, edema e congestão. Empregaram-se ANOVA e T-Student com p≤0,05 para as análises estatísticas. Resultados: no décimo quinto dia pós-HP e tratamento com BV, não ocorreram diferenças nas avaliações ponderais (p=0,0691), na função hepática e nos índices mitóticos (p=0,1576). Porém, houve diminuição na viabilidade celular (p=0,0000), densidade microvascular (p=0,0162) e piora na ocorrência de alterações histopatológicas como fibrose, edema e congestão hepáticas. Conclusão: a dose única de BV, não causou, ao décimo quinto dia de evolução, alterações ponderais, bioquímicas séricas (albumina, bilirrubinas e transaminases) e dos índices mitóticos. Contudo induziu diminuição da densidade microvascular, viabilidade celular e alterações histopatológicas hepáticas como edema, congestão e fibrose.Coordenação de Aperfeiçoamento de Pessoal de Nível Superiorapplication/pdfSOUSA, Eros Luiz de. Estudo experimental da inibição do VEGF na regeneração hepática. 2019. 135 p. Tese( Princípios da Cirurgia) - Faculdade Evangélica Mackenzie do Paraná, Curitiba .https://dspace.mackenzie.br/handle/10899/28448Liver regenerationangiogenesis inhibitorsbevacizumabVEGFrats, wistarporUniversidade Presbiteriana Mackenziehttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessregeneração hepáticainibidores da ingiogênesebevacizumabVEGFratos wistarCNPQ::CIENCIAS DA SAUDEEstudo experimental da inibição do VEGF na regeneração hepáticainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisreponame:Biblioteca Digital de Teses e Dissertações do Mackenzieinstname:Universidade Presbiteriana Mackenzie (MACKENZIE)instacron:MACKENZIERepka, João Carlos Domingues9033132753691332Torres, Maria Fernanda Piolihttp://lattes.cnpq.br/4570739681544375Nicoluzzi, João Eduardo Lealhttp://lattes.cnpq.br/6966261370146302Nassif, Paulo Afonso Nuneshttp://lattes.cnpq.br/5902051031307945BrasilFaculdade Evangélica Mackenzie do Paraná (FEMPAR)UPMPrincípios da CirurgiaORIGINALEros Luiz de Souza._ (003).pdfDocumento principalapplication/pdf2360170https://dspace.mackenzie.br/bitstreams/a02f0601-ff5c-4cf5-bef8-ec603c1e7d32/downloadcf1ecf14ade49abcafee0227cca696d8MD51CC-LICENSElicense_urlapplication/octet-stream49https://dspace.mackenzie.br/bitstreams/87bc04d5-598b-4ac6-b362-e2a25896a5bd/download4afdbb8c545fd630ea7db775da747b2fMD52license_textapplication/octet-stream0https://dspace.mackenzie.br/bitstreams/da524730-b094-42bc-af34-73ef59c40268/downloadd41d8cd98f00b204e9800998ecf8427eMD53license_rdfapplication/octet-stream0https://dspace.mackenzie.br/bitstreams/d23a5b3f-3571-4147-9ca5-b6bce1f3c26d/downloadd41d8cd98f00b204e9800998ecf8427eMD54LICENSElicense.txttext/plain2108https://dspace.mackenzie.br/bitstreams/18bde073-66bc-4ba2-b5c2-8602c8eaaeb6/download1ca4f25d161e955cf4b7a4aa65b8e96eMD55TEXTEros Luiz de Souza._ (003).pdf.txtEros Luiz de Souza._ (003).pdf.txtExtracted texttext/plain243953https://dspace.mackenzie.br/bitstreams/d4a5816b-f151-4bf7-af3e-4e89a37d2946/download4d7d678c9d692805189ac645b7f7c570MD58THUMBNAILEros Luiz de Souza._ (003).pdf.jpgEros Luiz de Souza._ (003).pdf.jpgGenerated Thumbnailimage/jpeg1195https://dspace.mackenzie.br/bitstreams/951b39fe-6830-448d-9d0a-86bd51eddeb7/download45b99ae97d78286bb2f55803a30d5ae8MD5910899/284482022-03-14 21:12:55.139http://creativecommons.org/licenses/by-nc-nd/4.0/Acesso Abertooai:dspace.mackenzie.br:10899/28448https://dspace.mackenzie.brBiblioteca Digital de Teses e Dissertaçõeshttp://tede.mackenzie.br/jspui/PRIhttps://adelpha-api.mackenzie.br/server/oai/repositorio@mackenzie.br||paola.damato@mackenzie.bropendoar:102772022-03-14T21:12:55Biblioteca Digital de Teses e Dissertações do Mackenzie - Universidade Presbiteriana Mackenzie (MACKENZIE)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
dc.title.por.fl_str_mv Estudo experimental da inibição do VEGF na regeneração hepática
title Estudo experimental da inibição do VEGF na regeneração hepática
spellingShingle Estudo experimental da inibição do VEGF na regeneração hepática
Sousa, Eros Luiz de
regeneração hepática
inibidores da ingiogênese
bevacizumab
VEGF
ratos wistar
CNPQ::CIENCIAS DA SAUDE
title_short Estudo experimental da inibição do VEGF na regeneração hepática
title_full Estudo experimental da inibição do VEGF na regeneração hepática
title_fullStr Estudo experimental da inibição do VEGF na regeneração hepática
title_full_unstemmed Estudo experimental da inibição do VEGF na regeneração hepática
title_sort Estudo experimental da inibição do VEGF na regeneração hepática
author Sousa, Eros Luiz de
author_facet Sousa, Eros Luiz de
author_role author
dc.contributor.advisor1Lattes.fl_str_mv http://lattes.cnpq.br/0300957415364593
dc.contributor.author.fl_str_mv Sousa, Eros Luiz de
dc.contributor.advisor1.fl_str_mv Malafaia, Osvaldo
dc.contributor.authorLattes.fl_str_mv http://lattes.cnpq.br/7564200346045204
contributor_str_mv Malafaia, Osvaldo
dc.subject.por.fl_str_mv regeneração hepática
inibidores da ingiogênese
bevacizumab
VEGF
ratos wistar
topic regeneração hepática
inibidores da ingiogênese
bevacizumab
VEGF
ratos wistar
CNPQ::CIENCIAS DA SAUDE
dc.subject.cnpq.fl_str_mv CNPQ::CIENCIAS DA SAUDE
description Background: extensive liver resections and transplants of liver parts are possible thanks to its regenerative capacity which is dependent on vascular endothelial growth factor (VEGF) activation which also regulates the angiogenesis. Bevacizumab (BV), a monoclonal antibody VEGF inhibitor, is a neoadjuvant treatment of cancers widely used, restricting microvascular density and may cause undesirable effects on postoperative healing and liver regeneration (LR). Objective: to determine the effect of a single dose (5mg/kg) of BV in LR. Methods: 32 rats submitted to partial hepatectomy (PH) were separated into two groups according to saline solution (C) or BV (BV) treatment. According to the observation time (48h and 15 days) they were subdivided in C48 and BV48 and C15 and BV15 sub-groups. In LR, the BV effects were evaluated by weight variation and liver function (albumin, transaminase, bilirubin and APRI ratio) and in remaining liver were evaluated, mitotic activity, microvascular density (angiogenesis), nuclear proliferation, histopathology for fibrosis, edema and congestion. For statistical analysis, the ANOVA and T-Student test was used (of statistical significance when p≤0.05). Results: on the fifteenth day after PH and BV treatment, there were no differences in weight evaluations (p=0.0691), liver function and mitotic indexes (p=0.1576). However, there was a decrease in cell viability (p=0.0000), microvascular density (p = 0.0162) and worsening in the occurrence of histopathological changes such as liver fibrosis, edema and congestion. Conclusion: a single BV dose, on the fifteenth day of evolution has no significant effect in weight evolution, serum biochemical evaluations (albumin, bilirubin and transaminases) and mitotic index. However, it induced microvascular density decreased, cell viability and liver histopathological changes such as fibrosis, edema and congestion.
publishDate 2019
dc.date.issued.fl_str_mv 2019-01-09
dc.date.accessioned.fl_str_mv 2021-12-15T19:34:01Z
dc.date.available.fl_str_mv 2021-12-15T19:34:01Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
status_str publishedVersion
dc.identifier.citation.fl_str_mv SOUSA, Eros Luiz de. Estudo experimental da inibição do VEGF na regeneração hepática. 2019. 135 p. Tese( Princípios da Cirurgia) - Faculdade Evangélica Mackenzie do Paraná, Curitiba .
dc.identifier.uri.fl_str_mv https://dspace.mackenzie.br/handle/10899/28448
identifier_str_mv SOUSA, Eros Luiz de. Estudo experimental da inibição do VEGF na regeneração hepática. 2019. 135 p. Tese( Princípios da Cirurgia) - Faculdade Evangélica Mackenzie do Paraná, Curitiba .
url https://dspace.mackenzie.br/handle/10899/28448
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Presbiteriana Mackenzie
publisher.none.fl_str_mv Universidade Presbiteriana Mackenzie
dc.source.none.fl_str_mv reponame:Biblioteca Digital de Teses e Dissertações do Mackenzie
instname:Universidade Presbiteriana Mackenzie (MACKENZIE)
instacron:MACKENZIE
instname_str Universidade Presbiteriana Mackenzie (MACKENZIE)
instacron_str MACKENZIE
institution MACKENZIE
reponame_str Biblioteca Digital de Teses e Dissertações do Mackenzie
collection Biblioteca Digital de Teses e Dissertações do Mackenzie
bitstream.url.fl_str_mv https://dspace.mackenzie.br/bitstreams/a02f0601-ff5c-4cf5-bef8-ec603c1e7d32/download
https://dspace.mackenzie.br/bitstreams/87bc04d5-598b-4ac6-b362-e2a25896a5bd/download
https://dspace.mackenzie.br/bitstreams/da524730-b094-42bc-af34-73ef59c40268/download
https://dspace.mackenzie.br/bitstreams/d23a5b3f-3571-4147-9ca5-b6bce1f3c26d/download
https://dspace.mackenzie.br/bitstreams/18bde073-66bc-4ba2-b5c2-8602c8eaaeb6/download
https://dspace.mackenzie.br/bitstreams/d4a5816b-f151-4bf7-af3e-4e89a37d2946/download
https://dspace.mackenzie.br/bitstreams/951b39fe-6830-448d-9d0a-86bd51eddeb7/download
bitstream.checksum.fl_str_mv cf1ecf14ade49abcafee0227cca696d8
4afdbb8c545fd630ea7db775da747b2f
d41d8cd98f00b204e9800998ecf8427e
d41d8cd98f00b204e9800998ecf8427e
1ca4f25d161e955cf4b7a4aa65b8e96e
4d7d678c9d692805189ac645b7f7c570
45b99ae97d78286bb2f55803a30d5ae8
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Biblioteca Digital de Teses e Dissertações do Mackenzie - Universidade Presbiteriana Mackenzie (MACKENZIE)
repository.mail.fl_str_mv repositorio@mackenzie.br||paola.damato@mackenzie.br
_version_ 1813820059438546944